- In May 2021, Maypharm announced the launch of METOX, a novel botulinum toxin developed to reduce moderate to severe facial wrinkles caused by everyday expressions. This product introduction represents a strategic advancement in cosmetic dermatology, offering enhanced efficacy in aesthetic treatments. The development is expected to strengthen Maypharm’s presence in the global botulinum toxin market and cater to growing consumer demand for minimally invasive cosmetic solutions
- In 2021, Sihuan Pharmaceutical Holdings Group Ltd. received regulatory approval for its botulinum toxin product, Letybo50U. This milestone reflects the company’s ongoing efforts to expand its dermatological product line. The approval is likely to enhance Sihuan’s competitive position in the aesthetic medicine market, while also meeting the rising demand for effective anti-wrinkle treatments across key Asian markets
